Fascia’s role in the mind-body continuum: a novel target for integrative treatments in psychiatry - Top-Institutions - MDSpire

Fascia’s role in the mind-body continuum: a novel target for integrative treatments in psychiatry

  • By

  • S Mudasser Shah

  • Muhammad Jahangir

  • Ghada Saleh Alhudaithi

  • Chand Taneja

  • Fatimah Sayer Alharbi

  • Xiuyun Lin

  • April 30, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Psychiatry
    • Neuroscience
    • Integrative Medicine

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Psychiatry
    • Neuroscience
    • Integrative Medicine

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Psychiatry
    • Pain Medicine
    • Integrative Medicine

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Psychiatry
    • Neuroscience
    • Pain Medicine

  • #5

    University of Michigan
    University of Michigan

    Ann Arbor, MI

    Key Differentiators

    • Psychiatry
    • Integrative Medicine
    • Neuroscience

Original Source(s)

Fascia’s role in the mind-body continuum: a novel target for integrative treatments in psychiatry

  • by S Mudasser Shah, Muhammad Jahangir, Ghada Saleh Alhudaithi, Chand Taneja, Fatimah Sayer Alharbi, Xiuyun Lin

  • April 30, 2026

Related Content

Lifestyle, psychological and demographic predictors of anxiety: insights from a large-scale survey and machine learning analysis

Virtual Reality Interventions for Stress Reduction in the General Population: Systematic Review and Meta-Analysis of Randomized Controlled Trials

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.